Drug Targeting 1 Flashcards

1
Q

What are the three types of endothelial cell structures recognised?

A
  1. Continuous
  2. Fenestrated pancreas (gaps are 20-80 nm)
  3. Sinusoidal (liver) (gaps are up to 150nm)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe sinusoidal endothelial cell structure

A

Gaps between cells are up to 150nm
The basement membrane is discontinuous (spleen, bone marrow) or absent (liver)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What cells are involved in MPS?

A

Macrophages in blood circulation and Kupffer cells in the liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What size particle tends to be cleared by MPS?

A

0.1-7micrometres

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What charge particle is cleared by MPS?

A

negative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Are hydrophilic or hydrophobic particles cleared by MPS?

A

Hydrophobic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is one of the pathological changes to tissue due to some diseases?

A

Increased endothelial fenestration size up to 20nm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is important if you are using a non-degradable polymer for a polymer-drug conjugate?

A

Molecular mass - ensure it is <40kDa to ensure renal excretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What kind of functional groups are used for linkers in polymer-drug conjugates?

A

Amine
Carbamate
Esters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Name the drug, linker and polymer in Oncaspar

A

Drug: L-asparaginase (enzyme)
Linker: amide
Polymer: m-PEG (5kDa)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Name the drug, linker and polymer in PEG-Asys

A

Drug: Interferon alfa-2a
Linker: amide
Polymer: branched m-PEG (40 kDa)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Name the drug, linker and polymer in Neulasta (pegfilgrastim)

A

Drug: g-CSF
Linker: amide
Polymer: m-PEG (20kDa)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Name the drug, linker and polymer in PEG-intron

A

Drug: interferon alfa-2b
Linker: carbamate
Polymer: m-PEG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Name the drug and polymer in Adagen

A

Drug: adenosine deaminase
Polymer: PEG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Indication of Pegasys

A

Hepatitis C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Indication of Neulasta

A

Neutropenia

17
Q

Indication of Adagen

A

Immunodeficiency disease

18
Q

Indication of Oncaspar

A

Acute Lymphoblastic Leukemia

19
Q

What is Neulasta the biosimilar of?

20
Q

What is the drug in Cimzia?

A

Certolizumab pegol

21
Q

Indication of Cimzia

22
Q

How does Cyclophosphamide work?

A

There is increased enzyme activity in tumour cells - cyclophosphamide is given in active/ prodrug form and is only converted to active form in tumour cells

23
Q

How does Misonidazole work?

A

Takes advantage of the fact that tumour cells are often hypoxic which means that reductases are more active - Misonidazole is only toxic in hypoxic cells

24
Q

What is ADEPT?

A

Antibody-directed enzyme prodrug therapy

25
Q

Give an example of 2 systems which use ADEPT

A

5- Fluorocytosine is broken down by cytosine deaminase into 5-fluorouracil

Protax is broken down by B-lactamase into Taxol

26
Q

Give 4 targeting moieties commonly used

A
  • Folate
  • Aptamers
  • Oligopeptides
  • MABs - whole monoclonal antibodies or Fab fragments
27
Q

What is an RGD sequence?

A

Arginine-Glycine-Aspartic acid sequence found in ECM proteins and integrins which helps cells to stick to their surroundings. However, this can be non-specific and may stick to more cells than intended

28
Q

What is Cilengitide?

A

A cyclic RGD peptide
Targets αvβ3 and αvβ5 integrins → blocks angiogenesis (blood vessel growth to tumors)
Tested in glioblastoma, lung, and pancreatic cancers
Discontinued in EU due to limited success in trials

29
Q

Give an example of a humanised MAb

A

Trastuzumab

30
Q

Give an example of a chimeric MAb

31
Q

Give an example of a human MAb

A

Adalimumab